Vivos Therapeutics Exchanges $2.86M of Debt for 11.4M Shares, Diluting Existing Holders by ~52%

summarizeSummary

Vivos Therapeutics exchanged $2.86 million of Streeterville Capital debt for up to 11.4 million shares of common stock, increasing the share count by approximately 52% and reducing the note balance to $3.7 million.

check_boxKey Events · Financing and Capital Events · VVOS

• Debt-for-Equity Exchange with Streeterville

  Vivos exchanged $2,861,270 of Streeterville Note principal for up to 11,445,080 shares of common stock at an average price of $0.25 per share.

• Massive Dilution to Existing Holders

  Share count increases from 22,164,313 to 33,609,393 shares outstanding, representing approximately 52% dilution to existing shareholders.

• Debt Reduction

  The outstanding principal balance of the Streeterville Note is reduced from $6.56 million to $3.7 million following the exchange.

• Immediate Selling Pressure

  Exchange Shares are issued without restrictive legends and can be sold immediately, subject to a 4.9% beneficial ownership limitation and sell-down condition.

auto_awesomeAnalysis · VVOS · Industrial Applications And Services

Vivos Therapeutics is converting $2.86 million of its Streeterville Capital debt into up to 11.4 million shares of common stock at an average price of $0.25 per share. The exchange reduces the outstanding principal balance of the Streeterville Note from $6.56 million to $3.7 million, but it comes at a steep cost: the share count jumps from 22.2 million to 33.6 million, meaning existing shareholders are diluted by roughly 52%. The shares are being issued without restrictive legends and can be sold immediately, creating significant overhang on a stock already trading at $0.174. This is the latest in a series of debt-for-equity exchanges with Streeterville, and it underscores the company's ongoing financial distress and reliance on dilutive financing to manage its obligations.